Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5582046 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 6 Pages |
Abstract
To the best of our knowledge, the present study is the first description of PRES associated with DA-EPOCH. The key risk factors for the development of PRES identified in our study included hypertension, fluid imbalance, electrolyte abnormalities, baseline organ dysfunction, a high tumor burden, and the presence of pre-existing CNS insults during chemotherapy, such as CNS infection. Patients with these risk factors appear to have a greater risk of developing PRES and should be monitored closely during treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Abby E. Floeter, Amila Patel, Melinda Tran, Marc C. Chamberlain, Paul C. Hendrie, Ajay K. Gopal, Ryan D. Cassaday,